Frequency Therapeutics Inc. (NASDAQ:FREQ) has a beta value of 0 and has seen 1,010,438 shares traded in the last trading session. The company, currently valued at $396.8 Million, closed the last trade at $11.61 per share which meant it gained $0.44 on the day or 3.94% during that session. The FREQ stock price is -402.76% off its 52-week high price of $58.37 and 36.78% above the 52-week low of $7.34. If we look at the company’s 10-day average daily trading volume, we find that it stood at 801.57 Million shares traded. The 3-month trading volume is 1.5 Million shares.
The consensus among analysts is that Frequency Therapeutics Inc. (FREQ) is an Overweight stock at the moment, with a recommendation rating of 2.2. 1 analysts rate the stock as a Sell, while none rate it as Overweight. None out of 5 have rated it as a Hold, with 4 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.28.
Frequency Therapeutics Inc. (NASDAQ:FREQ) trade information
Sporting 3.94% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Friday, Apr 30 when the FREQ stock price touched $12.19- or saw a rise of 4.76%. Year-to-date, Frequency Therapeutics Inc. shares have moved -67.07%, while the 5-day performance has seen it change 14.16%. Over the past 30 days, the shares of Frequency Therapeutics Inc. (NASDAQ:FREQ) have changed 36.43%. Short interest in the company has seen 6.08 Million shares shorted with days to cover at 4.05.
Wall Street analysts have a consensus price target for the stock at $19.75, which means that the shares’ value could jump 70.11% from current levels. The projected low price target is $10 while the price target rests at a high of $35. In that case, then, we find that the current price level is +201.46% off the targeted high while a plunge would see the stock lose -13.87% from current levels.
Frequency Therapeutics Inc. (FREQ) estimates and forecasts
Figures show that Frequency Therapeutics Inc. shares have outperformed across the wider relevant industry. The company’s shares have lost -47.03% over the past 6 months, with this year growth rate of 79.27%, compared to 8.1% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are -75% and -47.4% for the next quarter. Revenue growth from the last financial year stood is estimated to be +15.2%.
3 analysts offering their estimates for the company have set an average revenue estimate of $8.13 Million for the current quarter. 3 have an estimated revenue figure of $8.13 Million for the next quarter concluding in June 01, 2021. Year-ago sales stood $7.26 Million and $8.52 Million respectively for this quarter and the next, and analysts expect sales will grow by 11.9% for the current quarter and -4.6% for the next.
Earnings growth for 2021 is a modest -29.3%.
Frequency Therapeutics Inc. (NASDAQ:FREQ)’s Major holders
Insiders own 12.35% of the company shares, while shares held by institutions stand at 64.46% with a share float percentage of 73.54%. Investors are also buoyed by the number of investors in a company, with Frequency Therapeutics Inc. having a total of 169 institutions that hold shares in the company. The top two institutional holders are Wasatch Advisors Inc with over 3.48 Million shares worth more than $122.8 Million. As of December 30, 2020, Wasatch Advisors Inc held 10.19% of shares outstanding.
The other major institutional holder is Perceptive Advisors Llc, with the holding of over 3.26 Million shares as of December 30, 2020. The firm’s total holdings are worth over $114.93 Million and represent 9.54% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Wasatch Ultra Growth Fund and Wasatch Small Cap Growth Fund. As of December 30, 2020, the former fund manager holds about 3.28% shares in the company for having 1120938 shares of worth $39.52 Million while later fund manager owns 1.06 Million shares of worth $37.47 Million as of December 30, 2020, which makes it owner of about 3.11% of company’s outstanding stock.